AR109437A1 - Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades - Google Patents

Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades

Info

Publication number
AR109437A1
AR109437A1 ARP170102384A ARP170102384A AR109437A1 AR 109437 A1 AR109437 A1 AR 109437A1 AR P170102384 A ARP170102384 A AR P170102384A AR P170102384 A ARP170102384 A AR P170102384A AR 109437 A1 AR109437 A1 AR 109437A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
alkoxy
nhr11
hydroxy
Prior art date
Application number
ARP170102384A
Other languages
English (en)
Inventor
Ayako Honda
Sejal Patel
Rodrigo A Rodriguez
Dean Paul Phillips
Victor Ivanovich Nikulin
Robert Epple
Bei Chen
Mihai Azimioara
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR109437A1 publication Critical patent/AR109437A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se relaciona con compuestos capaces de modular la actividad de CFTR. Además, un método para fabricar los compuestos, su uso médico, en particular para su uso en el tratamiento y manejo de enfermedades o trastornos incluyendo fibrosis quística y trastornos relacionados. Reivindicación 1: Un compuesto de la fórmula (1), en donde: el anillo A es un anillo de arilo C₆₋₁₀; el anillo B es piridinilo; R¹ y R² son cada uno independientemente hidrógeno, nitrilo, alcoxilo C₁₋₄, alquilo C₁₋₄ halo-sustituido, cicloalquilo C₃₋₆ o alcoxilo C₁₋₄ halo-sustituido; R³ y R⁴ son cada uno independientemente hidrógeno, nitrilo, CD₃, cicloalquilo C₃₋₆, heterociclo C₄₋₆, alcoxilo C₁₋₄, halógeno, alquilo C₁₋₄, alquilo C₁₋₄ halo-sustituido, alquilo C₁₋₄ hidroxi-sustituido o alcoxilo C₁₋₄ halo-sustituido; n es 0, 1 ó 2; R⁵ es -NR⁷R⁸, -OR⁹ o R¹⁰; R⁶ es hidrógeno, hidroxilo, alquilo C₁₋₂, alcoxilo C₁₋₂, alquilo C₁₋₂ hidroxi-sustituido, halógeno o amino; m es 0, 1 ó 2; R⁷ es hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆, un heterociclo de 4 a 7 miembros completa o parcialmente saturado, en donde dicho heterociclo de 4 a 7 miembros es opcionalmente sustituido por 1 a 4 sustituyentes cada uno independientemente seleccionado a partir de halógeno, hidroxilo, alquilo C₁₋₄, alcoxilo C₁₋₄, -alquilo C₁₋₄ halo-sustituido, -alquilo C₁₋₄ hidroxi-sustituido, -alcoxilo C₁₋₄ halo-sustituido, oxo, nitrilo, cicloalquilo C₃₋₆, heterociclo C₄₋₆, NHR¹¹, -C(O)-R¹³, -C(O)NHR¹¹, alquilo C₁₋₃-C(O)NHR¹¹ y -C(O)O-R¹²; R⁸ es hidrógeno o alquilo C₁₋₄; R⁹ es hidrógeno, cicloalquilo C₃₋₆ o un heterociclo de 4 a 7 miembros completamente o parcialmente saturado cada anillo es opcionalmente sustituido por uno a cuatro sustituyentes cada uno independientemente seleccionado a partir de halógeno, hidroxi, alquilo C₁₋₄, alcoxilo C₁₋₄, alquilo C₁₋₄ halo-sustituido, alquilo C₁₋₄ hidroxi-sustituido, alcoxilo C₁₋₄ halo-sustituido, oxo, nitrilo, cicloalquilo C₃₋₆, heterociclo C₄₋₆, NHR¹¹, -C(O)-R¹³, -C(O)NHR¹¹, alquilo C₁₋₃-C(O)NHR¹¹ y -C(O)O-R¹²; R¹⁰ es un heterociclo de 4 a 10 miembros completa o parcialmente saturado opcionalmente sustituido por uno a cuatro sustituyentes cada uno independientemente seleccionado a partir de halógeno, hidroxilo, alquilo C₁₋₄, alcoxilo C₁₋₄, alquilo C₁₋₄ halo-sustituido, alquilo C₁₋₄ hidroxi-sustituido, alcoxilo C₁₋₄ halo-sustituido, oxo, nitrilo, cicloalquilo C₃₋₆, heterociclo C₄₋₆, NHR¹¹, -C(O)-R¹³, -C(O)NHR¹¹, alquilo C₁₋₃-C(O)NHR¹¹, -C(O)-alquilo C₁₋₃-NHR¹¹ y -C(O)O-R¹², en donde dicho cicloalquilo C₃₋₆ y heterociclo C₄₋₆ son opcionalmente sustituidos por 1 a 3 sustituyentes cada uno independientemente seleccionado a partir de hidroxilo, halógeno, amino, alquilo C₁₋₄, alquilo C₁₋₄ halo-sustituido y alquilo C₁₋₄ hidroxi-sustituido; R¹¹ es hidrógeno, alquilo C₁₋₄ o alquilo C₀₋₃-C(O)O-R¹⁴; R¹² es hidrógeno, alquilo C₁₋₄ o alquilo C₁₋₃-C(O)-NHR¹⁴; R¹³ es alquilo C₁₋₄, en donde dicho alquilo es opcionalmente sustituido por amino; y R¹⁴ es hidrógeno o alquilo C₁₋₄; o una sal farmacéuticamente aceptable del mismo.
ARP170102384A 2016-08-29 2017-08-29 Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades AR109437A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662380659P 2016-08-29 2016-08-29

Publications (1)

Publication Number Publication Date
AR109437A1 true AR109437A1 (es) 2018-11-28

Family

ID=59923496

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102384A AR109437A1 (es) 2016-08-29 2017-08-29 Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades

Country Status (15)

Country Link
US (2) US10450273B2 (es)
EP (1) EP3504194B1 (es)
JP (1) JP7035055B2 (es)
KR (1) KR20190040319A (es)
CN (1) CN109641873B (es)
AR (1) AR109437A1 (es)
AU (1) AU2017319430A1 (es)
BR (1) BR112019003883A2 (es)
CA (1) CA3031073A1 (es)
EA (1) EA201990609A1 (es)
ES (1) ES2898069T3 (es)
MX (1) MX2019002439A (es)
TW (1) TW201811766A (es)
UY (1) UY37379A (es)
WO (1) WO2018042316A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201811766A (zh) * 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
KR20180030363A (ko) 2016-09-13 2018-03-22 삼성디스플레이 주식회사 표시 장치
CN112638898B (zh) * 2018-08-31 2024-04-09 泽农医药公司 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途
JP2022514253A (ja) * 2018-12-18 2022-02-10 ノバルティス アーゲー Ｎ－（ピリジン－２－イルスルホニル）シクロプロパンカルボキサミド誘導体及びｃｆｔｒ媒介疾患の処置におけるその使用
BR112021011643A2 (pt) * 2018-12-21 2021-09-08 Novartis Ag Compostos macrocíclicos e seu uso no tratamento de doença
WO2020161623A1 (en) * 2019-02-06 2020-08-13 Novartis Ag N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
BR112022009185A2 (pt) * 2019-11-12 2022-07-26 Genzyme Corp Heteroarilaminossulfonamidas de 5 membros para tratar afecções mediadas por atividade de cftr deficiente
IL292965A (en) * 2019-11-12 2022-07-01 Genzyme Corp Heteroarylaminosulfonamides with 6 positions and methods of using them
WO2021114207A1 (en) * 2019-12-13 2021-06-17 Rhodia Operations Production of benzene derivatives
AU2021329507A1 (en) 2020-08-20 2023-03-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating respiratory diseases characterized by mucus hypersecretion

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
US5939431A (en) * 1996-06-20 1999-08-17 Schering Corporation Naphthyridines which affect IL-4 and G-CSF
TW520362B (en) 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
ATE454378T1 (de) 2002-11-01 2010-01-15 Vertex Pharma Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
SE0301654D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
EP1679309A4 (en) 2003-10-24 2007-03-28 Ono Pharmaceutical Co ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
CN1946703A (zh) 2004-04-20 2007-04-11 特兰斯泰克制药公司 取代的噻唑和嘧啶衍生物作为黑素细胞皮质激素受体调节剂
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
CA2576993C (en) 2004-08-12 2013-09-24 Amgen Inc. Bisaryl-sulfonamides
KR100874313B1 (ko) 2004-10-04 2008-12-18 에프. 호프만-라 로슈 아게 당뇨병을 치료하기 위한 11-베타 억제제로서의 알킬-피리딘
EP1666467A1 (en) 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitors
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
EP1922068A4 (en) 2005-08-16 2010-08-11 Icagen Inc INHIBITORS OF VOLTAGE-CONTROLLED SODIUM CHANNELS
EP1919877A1 (en) 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
CN101484452A (zh) 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 噻唑衍生物及其作为抗肿瘤药物的用途
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
DE602007012261D1 (de) 2006-07-14 2011-03-10 Chemocentryx Inc Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
EP2420494B1 (en) 2006-08-16 2014-10-08 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase
AR062677A1 (es) 2006-09-08 2008-11-26 Novartis Ag Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
US8084454B2 (en) 2007-04-11 2011-12-27 Canbas Co., Ltd. Compounds with anti-cancer activity
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
EP2211615A4 (en) 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
JP2011511056A (ja) 2008-02-05 2011-04-07 ファイザー・インク Ｃｎｓ障害および代謝障害治療のためのピリジニルアミド
EA201001847A1 (ru) 2008-06-11 2011-08-30 Айрм Ллк Соединения и композиции, применяемые для лечения малярии
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
CN102458122A (zh) * 2009-04-20 2012-05-16 人类健康研究所 含有哒嗪磺胺衍生物的化合物、组合物和方法
EP2253617A1 (de) 2009-05-20 2010-11-24 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
ES2626601T3 (es) 2010-06-28 2017-07-25 Bayer Intellectual Property Gmbh Compuestos heterocíclicos como pesticidas
WO2012004293A2 (de) 2010-07-08 2012-01-12 Bayer Cropscience Ag Insektizide und fungizide wirkstoffkombinationen
KR20130119964A (ko) 2010-12-22 2013-11-01 퍼듀 퍼머 엘피 나트륨 채널 차단제로서의 치환된 피리딘
US9295676B2 (en) 2011-03-17 2016-03-29 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of EGFR
EP2755652B1 (en) * 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
US9505728B2 (en) * 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
DK2888251T3 (da) 2012-08-21 2019-07-29 Peter Maccallum Cancer Inst Perforinhæmmende benzensulfonamidforbindelser, fremstilling og anvendelser deraf
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
EP2968285A4 (en) 2013-03-13 2016-12-21 Flatley Discovery Lab COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
US20170002011A1 (en) 2013-12-23 2017-01-05 Norgine B.V. Benzene sulfonamides as ccr9 inhibitors
EP3116870A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
SG10201913603QA (en) 2014-10-06 2020-02-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CN104844566B (zh) 2014-12-12 2018-05-18 合肥中科普瑞昇生物医药科技有限公司 一种新型结构的激酶抑制剂
US10047051B2 (en) 2015-06-02 2018-08-14 Abbvie S.Á.R.L. Substituted pyridines and method of use
US9981945B2 (en) * 2015-10-07 2018-05-29 NuBridge BioSciences Pyrimidine derivatives as CFTR modulators
GB201602527D0 (en) * 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途

Also Published As

Publication number Publication date
UY37379A (es) 2018-03-23
AU2017319430A1 (en) 2019-02-14
ES2898069T3 (es) 2022-03-03
US10450273B2 (en) 2019-10-22
US11066369B2 (en) 2021-07-20
MX2019002439A (es) 2019-07-08
JP7035055B2 (ja) 2022-03-14
KR20190040319A (ko) 2019-04-17
CN109641873B (zh) 2022-03-18
EA201990609A1 (ru) 2019-07-31
CA3031073A1 (en) 2018-03-08
BR112019003883A2 (pt) 2019-06-18
EP3504194B1 (en) 2021-08-18
JP2019530739A (ja) 2019-10-24
CN109641873A (zh) 2019-04-16
US20180072673A1 (en) 2018-03-15
TW201811766A (zh) 2018-04-01
US20200002281A1 (en) 2020-01-02
EP3504194A1 (en) 2019-07-03
WO2018042316A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
AR109437A1 (es) Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades
AR110139A1 (es) COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
PE20190348A1 (es) Moduladores de la via de estres integrada
AR104362A1 (es) Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR089284A1 (es) Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
AR112216A1 (es) Derivados de azaquinolina
AR107927A1 (es) Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR095371A1 (es) Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmológicos
AR096846A1 (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
AR116114A1 (es) Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
PE20220386A1 (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR097773A1 (es) Compuesto y composición farmacéuticamente aceptable, útil para tratar afección o trastorno mediano por actividad quinurenina 3-mono-oxigenasa
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
PE20181328A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
ECSP19084722A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
AR111474A1 (es) Compuestos químicos
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento

Legal Events

Date Code Title Description
FB Suspension of granting procedure